BBOT BRIDGEBIO ONCOLOGY THERAPEUT revenue, earnings and financials
For the quarter ended June 30, 2026, BRIDGEBIO ONCOLOGY THERAPEUT reported revenue of n/a, net income of −$56.5M and diluted EPS of −$705.20; for the fiscal year ended December 2025 revenue was n/a.
BBOT annual revenue and earnings
- Fiscal year ended Dec 2025: revenue n/a, gross profit n/a, operating income −$146M, net income −$134M (margin n/a), EPS −$4.30
- Fiscal year ended Dec 2024: revenue n/a, gross profit n/a, operating income −$80.9M, net income −$74.3M (margin n/a), EPS −$5756.41
- Fiscal year ended Dec 2023: revenue n/a, gross profit n/a, operating income −$41.7K, net income −$41.7K (margin n/a), EPS n/a
BBOT quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$56.5M, EPS −$705.20
- Quarter ended Mar 31, 2026: revenue n/a, net income −$42.1M, EPS −$526.11
- Quarter ended Dec 31, 2025: revenue n/a, net income −$38.8M, EPS −$0.49
- Quarter ended Sep 30, 2025: revenue n/a, net income −$44.8M, EPS −$1.03
- Quarter ended Jun 30, 2025: revenue n/a, net income −$28.4M, EPS −$566.46
- Quarter ended Mar 31, 2025: revenue n/a, net income −$22.1M, EPS −$54.23
- Quarter ended Dec 31, 2024: revenue n/a, net income −$19.7M, EPS −$1075.56
- Quarter ended Sep 30, 2024: revenue n/a, net income −$17.3M, EPS −$1562.18
- Quarter ended Jun 30, 2024: revenue n/a, net income −$21.8M, EPS n/a
- Quarter ended Mar 31, 2024: revenue n/a, net income −$15.4M, EPS n/a
BBOT cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$114M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$55.0M, share buybacks n/a
BBOT balance sheet
- Jun 30, 2026: cash $54.1M, total assets $377M, total liabilities $53.6M, shareholders' equity $323M
- Mar 31, 2026: cash $52.7M, total assets $418M, total liabilities $45.4M, shareholders' equity $372M
- Dec 31, 2025: cash $374M, total assets $448M, total liabilities $37.3M, shareholders' equity $411M
- Sep 30, 2025: cash $409M, total assets $485M, total liabilities $38.1M, shareholders' equity $447M
- Jun 30, 2025: cash n/a, total assets $197M, total liabilities $8.15M, shareholders' equity −$228M
- Mar 31, 2025: cash n/a, total assets $196M, total liabilities $7.39M, shareholders' equity −$200M
- Dec 31, 2024: cash $30.9M, total assets $164M, total liabilities $19.6M, shareholders' equity −$179M
- Sep 30, 2024: cash n/a, total assets $192M, total liabilities $5.65M, shareholders' equity −$159M
Is BBOT profitable?
No. BRIDGEBIO ONCOLOGY THERAPEUT lost $182M over the last four quarters.
What is BBOT's EPS?
Diluted earnings per share over the last four quarters were −$1232.83; −$705.20 in the latest quarter.